TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00822744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR411298
Description: Form: capsule~Route: oral administration with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR411298
Description: Form: capsule~Route: oral administration with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR411298
Description: Form: capsule~Route: oral administration with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SSR411298)
Description: Form: capsule~Route: oral administration with food
Study: NCT01802112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrins
Description: 15 grams of Resistant maltodextrins per day dissolved in water during 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 15gr placebo
Study: NCT03389113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exersice
Description: Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exersice
Description: Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
Study: NCT04046705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic matched related haematopoietic stem cell transplantation
Description: Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen

Intervention type: OTHER
Group type: OTHER
Intervention: Standard arm
Description: In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
Study: NCT00452348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Description: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250 mcg BID
Description: Fluticasone propionate 250 mcg BID
Study: NCT03577535

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin®
Description: Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
Study: NCT02466490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Fimasartan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan; Hydrochlorothiazide
Description: Fimasartan plus hydrochlorothiazide fixed dose combination tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan; Hydrochlorothiazide
Description: Fimasartan plus hydrochlorothiazide fixed dose combination tablets
Study: NCT03769428

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham erector spinae plane block
Description: The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
Study: NCT04224753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00027
Description: Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
Study: NCT03314376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Description: The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression.
Study: NCT03922555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
Study: NCT01250730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
Study: NCT03051945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT02463981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)
Study: NCT03044210

Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic evaluation
Description: * diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)

Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic evaluation
Description: * diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)
Study: NCT03632031

Intervention type: DEVICE
Intervention: Oasis Extracellular Matrix
Description: Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
Study: NCT00911274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 250 mg Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept®
Description: 250 mg Capsule
Study: NCT01398475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally
Study: NCT01946100

Intervention type: GENETIC
Group type: OTHER
Intervention: Multifocal Lung Adenocarcinoma
Description: Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
Study: NCT03056430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Study: NCT00432679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (BRL49653C)
Description: study drug
Study: NCT03709095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint interval training
Description: Participants utilized the arm ergometer for improving aerobic exercise capacity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity continuous training
Description: Participants utilized the arm ergometer for improving aerobic exercise capacity
Study: NCT01943825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT00997412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Description: 180 mg/tablet, 4 tablets twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZA
Description: 1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
Study: NCT03248466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRG combined with BMMSCs transplantation
Description: PRG combined with BMMSCs transplantation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRG combined with BMMSCs transplantation
Description: PRG combined with BMMSCs transplantation
Study: NCT01943825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01720602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study: NCT01388010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-Fermented Probiotic Dairy Product (test)

Intervention type: OTHER
Group type: OTHER
Intervention: 2-Milk-based non-fermented dairy product(control)
Study: NCT01720602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO
Study: NCT02209597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion XL 300
Description: Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics).
Study: NCT04176822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational animated movie group
Description: Watching educational animation movie which were designed by the researcher before operation for fear and pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Documentary movie group
Description: Watching documentary movie about trees before operation for fear and pain.
Study: NCT01720602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 16 alpha-fluoroestradiol
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05004168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day Gel-0120
Description: Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P5 Reference Standard (SPF 35 reference)
Description: The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.
Study: NCT02849223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial Direct Current Stimulation
Description: 2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
Study: NCT01732523

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast enhanced carotid ultrasound
Study: NCT02370693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
Study: NCT04038775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteering
Description: Subjects recommended volunteer by their provider.
Study: NCT05113524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
Study: NCT00749099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pancrelipase
Description: The test drug (PANCRECARB® \[pancrelipase\] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
Study: NCT01972477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1449
Description: Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1449
Description: Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
Study: NCT02370693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
Study: NCT00747071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Daily administration of Colostrum derived antibodies against C. difficile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Daily administration of Colostrum derived antibodies against C. difficile.
Study: NCT01044693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Description: Nebivolol 5mg single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol tartrate 50 mg
Description: metoprolol tartrate 50 mg single oral dose
Study: NCT01923389

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
Study: NCT01044693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil25 mg
Description: Sildenafil 25 mg single oral dose
Study: NCT03460964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive glucose sensor
Description: Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
Study: NCT02609451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileostomy closure
Description: Ileostomy closure at a different time point
Study: NCT01972477

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given every day for 8 weeks.
Study: NCT02940665

Intervention type: OTHER
Intervention: ERAS
Description: Patients in the ERAS group received the ERAS protocol
Study: NCT00471471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
Study: NCT03158779

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT and chemotherapy
Description: Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
Study: NCT00471471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF3512676
Description: 0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
Study: NCT03741439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter